Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety, biodistribution, and image quality of Copper Cu64 PSMA I&T injection to detect metastatic prostate cancer in PET imaging.
Michael Patterson, CEO – North America at Curium commented, “We are pleased to complete the Phase 1/2 SOLAR study enrollment ahead of schedule. We are excited to use Curium’s centralized Copper-64 production capabilities and our industry leading distribution network in upcoming Phase 3 trials. As we work globally to redefine the experience of cancer through our trusted legacy in nuclear medicine, we remain focused on driving innovation to improve the lives of more than 14 million patients each year.”
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “Completing the enrollment of patients for the SOLAR study is not only an important milestone for the study itself, but also a testament to the hard work and dedication of our investigators. We are very pleased with the clinical development progress of Cu-64-PSMA-I&T. After the completion of our analysis, we look forward to collaborating with our future investigators to start our Phase 3 program looking into the use of Cu-64-PSMA-I&T in patients with prostate cancer for initial staging and also for biochemical recurrence.”
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. There will be an estimated 288,000 new cases of prostate cancer in 2023.
For more information about the SOLAR trial: https://www.curiumpharma.com/resources/current-clinical-trials/solar-clinical-trial/
To locate a clinical trial site or contact Curium’s SOLAR clinical trial team: solar@curiumpharma.com
About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com
For more information:
Ross Bethell
VP, Head of Global Communications
communications@curiumpharma.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Financière de Tubize - Dividend approval27.4.2024 08:00:00 CEST | Press release
Dividend confirmation Regulated information - 26 april 2024 The general shareholders meeting of 26 April 2024 has approved the annual accounts as at 31 December 2023, including the distribution of a gross dividend of € 0.97 per share. The dividend will be payable as from 3 May 2024 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 19. Ex-coupon 30 April 2024 Record date 2 May 2024 Payment date 3 May 2024
EPH European Property Holdings PLC announces 2023 Year-End Result26.4.2024 23:55:00 CEST | Press release
26 April 2024, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS 2023 Despite the challenging market environment, EPH European Property Holdings PLC (“EPH” or the “Company”) maintained operational stability in 2023. This success can be attributed to its established portfolio of high-quality properties in prime locations in Europe, and professional asset management. As a result, EPH once again achieved almost full occupancy throughout its European portfolio, and exceeded own expectations by increasing net rental income by 26 percent compared to the previous year.As of 31 December 2023, EPH’s real estate portfolio consisted of eight core assets (and one parking garage) in outstanding locations in Germany and Vienna, all of which meet high sustainability standards. Seven out of eight office and hotel buildings have already been awarded certificates in DGNB Platinum, DGNB Gold, or LEED Gold.A milestone in the operating business was the completion of the LASS
FRO – Filing of Annual Report26.4.2024 22:36:43 CEST | Press release
Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2023. The annual report can be downloaded from the Company’s website www.frontlineplc.cy or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at: John Kennedy 8 Iris Building, 7th floor, Flat/Office 740B, 3106, Limassol, Cyprus. or sending an e-mail to ir@frontmgt.no April 26, 2024 Frontline plc Limassol, Cyprus. Questions should be directed to: Lars H. Barstad: Chief Executive Officer, Frontline Management AS +47 23 11 40 00 Inger M. Klemp: Chief Financial Officer, Frontline Management AS +47 23 11 40 00 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachments 5493004BCIKYU1YL3H63-2023-12-31-enAnnual Report 2023
Kallelse till årsstämma 2024 i Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Pressemelding
Aktieägarna i Fingerprint Cards AB (publ), org. nr. 556154-2381 (”Bolaget” eller ”Fingerprint”), kallas härmed till årsstämma klockan 15.00 tisdagen den 28 maj 2024 på GT30 (mötesrum ”Bond”), Grev Turegatan 30 i Stockholm. Styrelsen har, i enlighet med Bolagets bolagsordning, beslutat att aktieägarna före årsstämman ska ha möjlighet att utöva sin rösträtt genom poströstning. Aktieägare kan därmed välja att utöva sin rösträtt vid stämman personligen, genom ombud eller genom poströstning. A. Rätt att delta på stämman Aktieägare som önskar delta vid årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken måndagen den 20 maj 2024, och anmäla sin avsikt att delta vid stämman till Bolaget i enlighet med anvisningarna under avsnitt ”B. Anmälan för deltagande personligen eller genom ombud” senast onsdagen den 22 maj 2024, eller avge en poströst i enlighet med anvisningarna under rubriken ”C.Anvisningar för poströstning” senast onsdagen den 22 maj 2024. För att ha rätt att del
Notice to attend the 2024 Annual General Meeting of Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Press release
The shareholders of Fingerprint Cards AB (publ), Corp. Reg. No. 556154-2381 (hereinafter referred to as the “Company” or “Fingerprint”)), are hereby invited to attend the Annual General Meeting (“AGM” or the “Meeting”) to be held at 3:00 p.m. on Tuesday, May 28, 2024, at GT30 (meeting room “Bond”), Grev Turegatan 30 in Stockholm. The Board of Directors has decided, pursuant to the Company’s articles of association, that shareholders shall also have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the Meeting by attending in person, through a proxy or by postal voting. A. Right to participate in the Meeting In order to participate in the Meeting, a shareholder shall: be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, May 20, 2024, and give notice of attendance at the Meeting to the Company in accordance with the instructions set out in the section “B. Notice of atte